Company / Operating Cash Flow
Inmune Bio, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$33.4M
FY2025
5-year range
-$33.4M / -$8.9M
FY2021-FY2025
Trend
-178.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$23M to -$33M over the past 2 years.
Based on SEC 10-K filings.
-$33M in FY2025.
Declined from -$23M to -$33M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 178.5% year-over-year.
- Peak operating cash flow was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 49.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$33.4M | -178.5% |
| FY2024 | -$12.0M | +47.2% |
| FY2023 | -$22.7M | +20.4% |
| FY2022 | -$28.5M | -218.7% |
| FY2021 | -$8.9M | -66.1% |
| FY2020 | -$5.4M | -606.8% |
| FY2018 | -$761.8K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026